NasdaqGM:NRIXBiotechs
Nurix Therapeutics (NRIX) Heavy Q1 Net Loss Reinforces Bearish Narrative On Profitability
Nurix Therapeutics (NRIX) opened 2026 with Q1 revenue of US$6.3 million and a basic EPS loss of US$0.79, while trailing twelve month figures show revenue of US$71.8 million against a basic EPS loss of US$3.17, framing a business that is still firmly in investment mode. Over the past year, the company has seen quarterly revenue range from US$6.3 million to US$44.1 million and basic EPS move between a loss of US$0.52 and a loss of US$1.03, giving investors a clear view of how top line progress...